Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Dr Reddy’s Laboratories ( (RDY) ) just unveiled an announcement.
Dr. Reddy’s Laboratories announced on May 10, 2025, that it has published its audited financial results for the quarter and year ended March 31, 2025. These results were advertised in the Business Standard and Andhra Prabha newspapers. This disclosure is in compliance with the Securities and Exchange Board of India’s regulations, which underscores the company’s commitment to transparency and regulatory adherence.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
Dr Reddy’s Laboratories receives a solid overall score due to its strong financial performance, especially in revenue growth and balance sheet stability. Technical indicators show positive momentum, although the stock is below its long-term average. Valuation is reasonable, but dividend yield is low. The recent earnings call was positive, highlighting growth and strategic advancements despite some market challenges.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is a pharmaceutical company based in Hyderabad, India. It is involved in the development and manufacturing of generic medications, active pharmaceutical ingredients, and over-the-counter products. The company is listed on multiple stock exchanges, including the National Stock Exchange of India, BSE Limited, and the New York Stock Exchange.
Average Trading Volume: 2,186,475
Technical Sentiment Signal: Hold
Current Market Cap: $11.39B
See more insights into RDY stock on TipRanks’ Stock Analysis page.